Dr. Vidal on the Lasting Impact of the KATHERINE Trial in HER2-Positive Breast Cancer

Gregory Vidal, MD, PhD, medical oncologist, the West Cancer Center & Research Institute, discusses the impact of the phase 3 KATHERINE trial (NCT01772472) in HER2-positive breast cancer.

The 2-arm, randomized, open-label study evaluated the safety and efficacy of trastuzumab emtansine (T-DM1; Kadcyla) compared with trastuzumab (Herceptin) in the adjuvant setting for patients with HER2-positive breast cancer.

The KATHERINE trial changed how clinicians approach patients with HER2-positive breast cancer, as T-DM1 achieved activity in the high-risk, HER2-positive subgroup, Vidal says. This provided another treatment option beyond traditional chemotherapy, Vidal explains.

The results of KATHERINE has a bigger effect on the breast cancer landscape than the phase 3 FeDeriCa trial (NCT03493854), Vidal concludes.